Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
contrast agent
gadolinium-based contrast agent |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
V08CA05
|
| gptkbp:CASNumber |
129729-25-3
|
| gptkbp:containsElement |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:hasMolecularFormula |
C18H31GdN4O10
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadoversetamide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
OptiMARK
|
| gptkbp:molecularWeight |
661.72 g/mol
|
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
headache injection site reaction |
| gptkbp:usedFor |
magnetic resonance imaging
|
| gptkbp:bfsParent |
gptkb:gadolinium-based_contrast_agents
|
| gptkbp:bfsLayer |
7
|